Methyl 3-(2,4-Dichlorophenyl)Acrylate

Methyl 3-(2,4-Dichlorophenyl)Acrylate

SCHEMBL7434845

COC(=O)C=Cc1ccc(Cl)cc1Cl

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.62
ALDH1A1 P00352 6/20 0.62
KDM4E B2RXH2 3/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
GAA P10253 1/20 0.62
KMT2A Q03164 7/20 0.59
MEN1 O00255 6/20 0.59
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
POLB P06746 2/20 0.57
NPSR1 Q6W5P4 2/20 0.54
LMNA P02545 4/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
HPGD P15428 3/20 0.53
GLA P06280 1/20 0.53
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
TP53 P04637 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl 3-(2,4-Dichlorophenyl)Acrylate SCHEMBL6315070 1.00 MAPT (0.62) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL3532294 0.87 ALDH1A1 (0.51) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL3532296 0.87 ALDH1A1 (0.51) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL14926720 0.85 MAPT (0.50) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL1745374 0.85 BACE1 (0.69) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL31155851 0.85 MAPT (0.58) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL672165 0.84 MAPT (0.49) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL3179934 0.84 ABL1 (0.51) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL8267197 0.84 MAPT (0.49) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL3173933 0.84 MAPT (0.49) MAPTALDH1A1KDM4EL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116234798-A Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders 生物药品解决方案有限公司 2023-06-06 CN disclosed
CN-106507667-B Sulfamate derivatives for the prevention or treatment of epilepsy 比皮艾思药物研发有限公司 2020-01-24 CN disclosed
EP-2935249-B1 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2018-12-12 EP disclosed
US-9630945-B2 Autotaxin inhibitors NOVARTIS AG (CH) 2017-04-25 US disclosed
US-20170007614-A1 Autotaxin inhibitors NOVARTIS AG (CH) 2017-01-12 US disclosed
US-9409895-B2 Autotaxin inhibitors NOVARTIS AG (CH) 2016-08-09 US disclosed
US-20150307475-A1 Autotaxin inhibitors NOVARTIS AG (CH) 2015-10-29 US disclosed
EP-2935249-A2 AUTOTAXIN INHIBITORS Novartis AG (CH) 2015-10-28 EP disclosed
EP-2861571-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME Bio-Pharm Solutions Co., Ltd. (KR) 2015-04-22 EP disclosed
WO-2014097151-A2 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2014-06-26 WO disclosed
US-20140171404-A1 Autotaxin inhibitors NOVARTIS AG (CH) 2014-06-19 US disclosed
US-20140171403-A1 Autotaxin inhibitors NOVARTIS AG (CH) 2014-06-19 US disclosed
WO-2013187727-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-12-19 WO disclosed
CN-1284064-A 2,3-substituted indole compounds as cox-2 inhibitors PFIZER PHARMA (US) 2001-02-14 CN disclosed
EP-0526535-B1 CYCLIC HYDROXAMIC ACIDS AND THEIR USE ORION YHTYMAE OY (FI) 1995-09-27 EP disclosed
US-5356923-A 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and anti-hypertensive use thereof ORION-YHTYMA OY (FI) 1994-10-18 US disclosed
EP-0526535-A1 CYCLIC HYDROXAMIC ACIDS AND THEIR USE. ORION YHTYMAE OY (FI) 1993-02-10 EP disclosed
WO-1991016303-A1 CYCLIC HYDROXAMIC ACIDS AND THEIR USE Orion-Yhtymä Oy (FI) 1991-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307475-A1 Autotaxin inhibitors ENPP2, ATXN10, ATXN2L MAPT 259/4885ALDH1A1 3712/4885KDM4E 3188/4885
US-20140171403-A1 Autotaxin inhibitors ENPP2, SERPINB1, TFPI MAPT 249/4885ALDH1A1 4843/4885KDM4E 4073/4885
US-20140171404-A1 Autotaxin inhibitors ENPP2, ATXN10, ATXN2L MAPT 160/4885ALDH1A1 4601/4885KDM4E 2714/4885
US-20170007614-A1 Autotaxin inhibitors ENPP2, SERPINB1, TFPI MAPT 249/4885ALDH1A1 4843/4885KDM4E 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.